Kommoss Stefan, Schmidt Dietmar, Kommoss Friedrich, Hedderich Juergen, Harter Philipp, Pfisterer Jacobus, du Bois Andreas
Department of Gynecology & Gynecologic Oncology, Dr.-Horst-Schmidt-Kliniken (HSK) Wiesbaden, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Germany.
Virchows Arch. 2009 Mar;454(3):249-56. doi: 10.1007/s00428-009-0725-y. Epub 2009 Jan 27.
While there is no doubt that histologic grading is applicable in early stage ovarian carcinoma, it is still in controversial discussion concerning advanced stage ovarian carcinoma. It was the aim of this study to assess the three most widely used grading systems for ovarian carcinoma in terms of prognostic significance, concordance rates, and reproducibility in a large number of advanced stage ovarian carcinomas of all types after standardized chemotherapy. Representative hematoxylin and eosin slides from 334 cases of stage IIB-IV ovarian carcinoma (prospective randomized, multi-center, phase III study) were used. The first round was grading of all cases according to FIGO, GOG, and Silverberg by one author. The second round (after 1 year) was 30 randomly selected cases graded by three authors. None of the three grading systems was prognostically significant (FIGO p = 0.38; GOG p = 0.70; Silverberg p = 0.92). The concordance rates between the three systems were as follows: FIGO/GOG 95.5%, kappa = 0.929; Silverberg/FIGO 69.9%, kappa = 0.533; Silverberg/GOG 66.8%, kappa = 0,481. Grading of advanced stage ovarian carcinomas was of no value for estimation of prognosis in this homogeneously treated patient group. Alternative methods should be defined, which might help to separate patients with high risk of tumor progression from others with low risk.
虽然毫无疑问组织学分级适用于早期卵巢癌,但对于晚期卵巢癌仍存在争议。本研究的目的是在标准化化疗后的大量各类晚期卵巢癌中,评估三种最广泛使用的卵巢癌分级系统的预后意义、一致率和可重复性。使用了来自334例IIB-IV期卵巢癌(前瞻性随机、多中心、III期研究)的代表性苏木精和伊红切片。第一轮由一位作者根据国际妇产科联盟(FIGO)、妇科肿瘤学组(GOG)和西尔弗伯格(Silverberg)系统对所有病例进行分级。第二轮(1年后)由三位作者对随机选择的30例病例进行分级。三种分级系统均无预后意义(FIGO p = 0.38;GOG p = 0.70;Silverberg p = 0.92)。三种系统之间的一致率如下:FIGO/GOG为95.5%,kappa = 0.929;Silverberg/FIGO为69.9%,kappa = 0.533;Silverberg/GOG为66.8%,kappa = 0.481。在这个经过同质化治疗的患者群体中,晚期卵巢癌的分级对预后评估没有价值。应该定义替代方法,这可能有助于将肿瘤进展风险高的患者与低风险患者区分开来。